InsiderTrades.com logo
America’s worst nightmare?
From Porter & Company   |   Ad
What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.
Click here to watch this bombshell exposé now.
Maha Katabi net worth and biography
  • LinkedIn
  • Phone
  • Website

Maha Katabi Biography and Net Worth

Director of RayzeBio

Maha Katabi is a General Partner at Sofinnova Investments. Dr. Katabi is an experienced investor with over two decades in managing public and private biotech companies through bull and bear markets. She is focused on investing in development stage biopharmaceuticals and is currently a member of the board of directors of Aerovate (AVTE), Quanta, and Vera (VERA), and was recently a board member of Gyroscope (acquired by Novartis) and Amplyx (acquired by Pfizer).

Prior to joining Sofinnova in 2019, Maha was Managing Partner of Oxalis Capital.  Prior to founding Oxalis, Maha was Partner at Sectoral Asset Management, where she formed and led a dedicated investment team and advisory board to drive investments in private companies. Two of these companies were Ascendis (ASND) and Apellis (APLS), both also Sofinnova portfolio companies. Additionally, she was a Portfolio Manager for a family of funds that invested in small cap healthcare companies. She started her career in venture as a principal investor with associate and principal roles at T2C2/Bio and Ventures West.

Maha received her BSc In Biology and PhD in Pharmacology from McGill University, where she was a Cancer Research Society fellow, and is a CFA charter holder since 2011. She currently serves as Chair of the board of Exactis Innovation, a not-for profit oncology precision medicine network.

What is Maha Katabi's net worth?

The estimated net worth of Maha Katabi is at least $174.60 million as of March 25th, 2024. Dr. Katabi owns 2,793,987 shares of RayzeBio stock worth more than $174,596,248 as of May 13th. This net worth evaluation does not reflect any other assets that Dr. Katabi may own. Learn More about Maha Katabi's net worth.

How do I contact Maha Katabi?

The corporate mailing address for Dr. Katabi and other RayzeBio executives is , , . RayzeBio can also be reached via phone at 619-937-2754. Learn More on Maha Katabi's contact information.

Has Maha Katabi been buying or selling shares of RayzeBio?

Maha Katabi has not been actively trading shares of RayzeBio within the last three months. Most recently, on Tuesday, September 19th, Maha Katabi bought 472,222 shares of RayzeBio stock. The stock was acquired at an average cost of $18.00 per share, with a total value of $8,499,996.00. Following the completion of the transaction, the director now directly owns 1,209,764 shares of the company's stock, valued at $21,775,752. Learn More on Maha Katabi's trading history.

Are insiders buying or selling shares of RayzeBio?

In the last year, RayzeBio insiders bought shares 2 times. They purchased a total of 1,861,111 shares worth more than $33,499,998.00. The most recent insider tranaction occured on September, 19th when Director Maha Katabi bought 472,222 shares worth more than $8,499,996.00. Learn More about insider trades at RayzeBio.

Information on this page was last updated on 9/19/2023.

Maha Katabi Insider Trading History at RayzeBio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/19/2023Buy472,222$18.00$8,499,996.001,209,764View SEC Filing Icon  
See Full Table

Maha Katabi Buying and Selling Activity at RayzeBio

This chart shows Maha Katabi's buying and selling at RayzeBio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

RayzeBio Company Overview

RayzeBio logo
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Read More

Today's Range

Now: $62.49
Low: $62.49
High: $62.49

50 Day Range

MA: $62.47
Low: $62.27
High: $62.49

2 Week Range

Now: $62.49
Low: $17.95
High: $62.51

Volume

N/A

Average Volume

553,592 shs

Market Capitalization

$3.74 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
America’s worst nightmare?
From Porter & Company   |   Ad
What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.
Click here to watch this bombshell exposé now.